Viewpoint Molecular Targeting, Inc.
Coralville, IA Doing business as Viewpoint Molecular Targeting Inc. Part of Perspective Therapeutics, Inc.
- UEI
- RDZCK3F6AU73
- CAGE
- 5HQZ4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Perspective Therapeutics, Inc.
Parent
QVKDNCDJL2X7
- Viewpoint Molecular Targeting, Inc. RDZCK3F6AU73
-
Perspective Therapeutics, Inc.
Parent
QVKDNCDJL2X7
- SAM.gov registration date
- Physical address
- 2500 Crosspark Rd e116, Coralville, IA 52241, USA
- Website
- perspectivetherapeutics.com
- Founded
- 2023
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Antibody-based prertargeted alpha particle therapy for ovarian cancer - project summary high-grade serous ovarian… | National Cancer Institute | $377,854 | |
| Image-guided dosimetry-based alpha particle therapy for neuroblastoma. - significance: neuroblastoma is the most… | National Cancer Institute | $3,932,125 | |
| Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for… | National Cancer Institute | $3,993,602 | |
| GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for PB-212… | National Cancer Institute | $3,999,532 | |
| Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic… | National Cancer Institute | $2,901,435 |
About Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. is a corporate entity registered in SAM.gov since 2009, located in Coralville, Iowa. The company appears to be a biotechnology research organization focused on developing targeted alpha-particle therapies for various cancer treatments. While specific details about the company's comprehensive background are not provided, its federal grant history indicates a specialized focus on innovative cancer therapy research and development, particularly in the domain of precision oncological interventions.
The company has received multiple federal grant awards from the National Cancer Institute (NCI) through Project Grant mechanisms, consistently targeting advanced cancer treatment technologies. These grants, each approximately $300,000-$400,000, have supported research into image-guided alpha-particle therapies for specific cancer types, including high-grade serous ovarian carcinoma (HGSOC), neuroblastoma, neuroendocrine tumors, and metastatic melanoma. The research involves developing sophisticated therapeutic approaches such as antibody-based pretargeting strategies, radionuclide production technologies, and innovative molecular targeting techniques. Each grant has focused on different aspects of therapeutic development, including validating monoclonal antibodies, optimizing radioligand formulations, conducting preclinical pharmacology and toxicology studies, and establishing protocols for potential future clinical trials. The company's work appears aimed at creating more precise, targeted cancer treatments that can potentially improve patient outcomes in cancers with historically poor prognoses.
Quick answers
What is Viewpoint Molecular Targeting, Inc.'s UEI?
Viewpoint Molecular Targeting, Inc.'s Unique Entity ID (UEI) in SAM.gov is RDZCK3F6AU73.
What is Viewpoint Molecular Targeting, Inc.'s CAGE code?
Viewpoint Molecular Targeting, Inc.'s CAGE code is 5HQZ4.
What is Viewpoint Molecular Targeting, Inc.'s primary NAICS code?
Viewpoint Molecular Targeting, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Viewpoint Molecular Targeting, Inc. located?
Viewpoint Molecular Targeting, Inc.'s physical address in SAM.gov is 2500 Crosspark Rd e116, Coralville, IA 52241, USA.
Is Viewpoint Molecular Targeting, Inc. registered in SAM.gov?
Yes. Viewpoint Molecular Targeting, Inc.'s SAM.gov registration is active through August 13, 2027.
Who is Viewpoint Molecular Targeting, Inc.'s parent company?
Viewpoint Molecular Targeting, Inc. is part of Perspective Therapeutics, Inc.
What is Viewpoint Molecular Targeting, Inc.'s most recent federal award?
Viewpoint Molecular Targeting, Inc.'s most recent federal grant award is Antibody-based prertargeted alpha particle therapy for ovarian cancer - project summary high-grade serous ovarian… (R42CA287696), from National Cancer Institute, on June 5, 2024.
On GovTribe
See Viewpoint Molecular Targeting, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors